Dianthus Therapeutics Q2 net loss widens as R&D costs rise
DNTH•Pipeline outlook and analyst view
Dianthus expects top-line results from the Phase 2 MoMeNtum trial in MMN in December 2026. The company also anticipates Phase 1 healthy volunteer data for DNTH212 by year-end 2026, and said DNTH312 aims to be Phase 1 ready by year-end 2027.
The current average analyst rating on the shares is strong buy, with 16 ratings of strong buy or buy, and no hold, sell, or strong sell ratings. Wall Street's median 12-month price target for Dianthus Therapeutics Inc is $125.00, about 17.9% above its August 3 closing price of $106.02.
Clinical progress and cash position
Dianthus said interim milestones were reached for claseprubart in CIDP and MMN, with ongoing and new trials initiated.
The company ended the second quarter with $1.2 billion in cash, which it expects will fund operations into 2030.
Q2 loss widens as operating expenses rise
US biotech firm Dianthus Therapeutics reported that its second-quarter net loss widened to .
